

Resource Summary Report

Generated by [nidm-terms](#) on Jul 31, 2026

EORTC

RRID:SCR_004070

Type: Tool

Proper Citation

EORTC (RRID:SCR_004070)

Resource Information

URL: <http://www.eortc.org/>

Proper Citation: EORTC (RRID:SCR_004070)

Description: An independent pan-European clinical research organization to improve the standards of cancer care through the multidisciplinary multinational efforts of basic scientists and clinicians. The efforts include the testing of more effective therapeutic strategies based on drugs, surgery and/or radiotherapy that are already in use. They also contribute to the development of new drugs and other approaches in partnership with the pharmaceutical industry which is accomplished mainly by conducting large, multicenter, prospective, randomized, phase III clinical trials. The EORTC Network comprises over 300 hospitals and cancer centers in over 30 countries which include some 2,500 collaborators from all disciplines involved in cancer treatment and research. The EORTC Headquarters staff handle some 6,000 new patients enrolled each year in cancer clinical trials, approximately 30 protocols that are permanently open to patient entry, over 50,000 patients who are in follow-up, and a database of more than 180,000 patients. Intergroup collaboration is also promoted to face current challenges of clinical trials aiming at targeted therapies in order to recruit a large number of patients within a reasonable period of time.

Abbreviations: EORTC

Synonyms: European Organisation for Research and Treatment of Cancer, European Organization for Research and Treatment of Cancer

Resource Type: nonprofit organization

Keywords: clinical, translational, drug, clinical research organization, drug development, clinical trial

Related Condition: Cancer

Resource Name: EORTC

Resource ID: SCR_004070

Alternate IDs: nlx_158510, grid.434691.d, Wikidata: Q50376884

Alternate URLs: <https://ror.org/04g9wby70>

Record Creation Time: 20220129T080222+0000

Record Last Update: 20260725T190547+0000

Ratings and Alerts

No rating or validation information has been found for EORTC.

No alerts have been found for EORTC.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 2873 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Neron M, et al. (2026) Prevention of postoperative complications with negative pressure wound therapy after complex breast cancer surgery: a study protocol of a randomised controlled trial (TPN-SEIN). *BMJ open*, 16(1), e103827.

Albert NL, et al. (2026) [177Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*, 67(1), 23.

Silva SRRC, et al. (2026) Photobiomodulation therapy in breast cancer-related acute radiodermatitis cases in Brazilian women: study protocol for a randomized controlled trial. *Trials*, 27(1), 2.

Fasching PA, et al. (2025) Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(9), 1625.

Callegaro D, et al. (2025) CINSARC and Sarculator in Patients with Primary Retroperitoneal Sarcoma: A Combined Analysis of Single-Institution Data and the EORTC-STBSG-62092 Trial (STRASS). *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(15), 3239.

Consolo L, et al. (2025) Implementation of the e-IPOS in Home Palliative Cancer Care: A Quasiexperimental Pilot Study. *The American journal of hospice & palliative care*, 42(2),

Zhao C, et al. (2025) Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial. *Signal transduction and targeted therapy*, 10(1), 249.

Dinh TH, et al. (2025) A comprehensive analysis of health-related quality of life in thyroid cancer patients using the THYCA-24 questionnaire. *Scientific reports*, 15(1), 29626.

Obara T, et al. (2025) Health-related quality of life in 62 patients with diffuse low-grade glioma during a non-therapeutic and progression-free phase: a cross-sectional study. *Journal of neuro-oncology*, 171(3), 659.

Akdemir E, et al. (2025) Long-term quality of life in patients with bladder cancer following radical cystectomy. *BJU international*, 135(4), 675.

Noronha V, et al. (2025) Pregabalin for chronic cough due to lung cancer: randomized, double-blind, placebo-controlled trial. *British journal of cancer*, 132(1), 58.

Lu X, et al. (2025) Symptom clusters and sentinel symptoms in breast cancer survivors based on self-reported outcomes: A cross-sectional survey. *Journal of clinical nursing*, 34(3), 1072.

Del Giudice F, et al. (2025) VI-RADS followed by Photodynamic Transurethral Resection of Non-Muscle-Invasive Bladder Cancer vs White-Light Conventional and Second-resection: the 'CUT-less' Randomised Trial Protocol. *BJU international*, 135(2), 346.

Hachem MA, et al. (2025) Quality of Life in Pediatric Oncology Patients in Lebanon (2014-2019): A Multi-center Study. *Cureus*, 17(1), e77000.

Roshan A, et al. (2025) Next day sentinel node biopsy for melanoma after lymphoscintigraphy using 99mTc-labelled nanocolloid does not adversely affect long-term outcomes. *Annals of nuclear medicine*, 39(1), 77.

Nies M, et al. (2025) Recovery of quality of life in 574 patients with inoperable lung cancer undergoing (chemo)radiotherapy. *Clinical and translational radiation oncology*, 52, 100935.

Gehrels AM, et al. (2025) Longitudinal health-related quality of life in patients with pancreatic cancer stratified by treatment: a nationwide cohort study. *EClinicalMedicine*, 80, 103068.

Gil-Ibañez B, et al. (2025) A multimodal intervention program to improve sexual health and self-perceived quality of life in patients treated for cervical cancer: a randomized prospective study (PROVIDENCE trial). *Journal of gynecologic oncology*, 36(4), e56.

Parent P, et al. (2025) Muscle Loss During First-Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity. *Journal of cachexia, sarcopenia and muscle*, 16(1), e13595.

Hsuan Chen Y, et al. (2025) Treatment-related toxicity, utility and patient-reported outcomes of head and neck cancer patients treated with proton therapy: A longitudinal study. *Clinical and translational radiation oncology*, 51, 100913.